Nevertheless, a subsequent study indicated that persistent inhibition of CSF-1R alone was inadequate for long-term tumor control due to drug resistance, and glioma growth resumed after an initial period of slow proliferation [3]. This evidence concerns the gene CSF1R and central nervous system cancer.